Evaluation of 3,606 Renal Cell Tumors for TFE3 Rearrangements and TFEB Alterations via Fluorescence in Situ Hybridization, Next Generation Sequencing, and GPNMB Immunohistochemistry - Beyond the Abstract
However, the morphologic spectrum of common renal cell carcinomas overlaps significantly with TFE3-rearranged renal cell carcinoma and TFEB-altered renal cell carcinoma such that ancillary testing is often pursued to evaluate for the possibility of this rare subset of renal cell carcinomas. To date, this is the largest investigation of these tumors. We provide our diagnostic criteria, morphological clues, and evaluate an emerging biomarker. Additionally, we provide commentary on the need for uniform criteria for establishing diagnosis/prognosis that currently do not exist.
Written by: Rumeal D. Whaley, MD, Assistant Professor of Laboratory Medicine and Pathology, Senior Associate Consultant, Head & Neck Pathology, Genitourinary Pathology, Endocrine Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
Read the Abstract